6160 — BeOne Medicines AG Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapHigh Flyer

Annual income statement for BeOne Medicines AG, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,120	7,589	9,566	17,423	27,214
Cost of Revenue
Gross Profit	1,634	6,528	7,663	14,713	22,951
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	13,367	17,168	22,992	26,234	31,376
Operating Profit	-11,247	-9,580	-13,425	-8,810	-4,162
Other Net Non Operating Costs
Net Income Before Taxes	-11,249	-9,579	-13,427	-6,208	-4,163
Provision for Income Taxes
Net Income After Taxes	-11,407	-9,748	-13,642	-6,716	-4,978
Minority Interest
Net Income Before Extraordinary Items
Net Income	-11,384	-9,748	-13,642	-6,716	-4,978
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-11,384	-9,748	-13,642	-6,716	-4,978
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-8.53	-7.3	-10.2	-4.95	-3.66
Dividends per Share